SEC Form 13F Information Table Summary
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Johnson & Johnson to the U.S. Securities and Exchange Commission. The reporting period covers holdings as of June 30, 2026. This form discloses the equity securities held by institutional investment managers, not the operating results of Johnson & Johnson itself.
Key Financial Metrics and Holdings
The filing details a portfolio of 15 equity positions, primarily concentrated in the biotechnology and healthcare sectors. The total value of reported holdings is not explicitly summed in the text, but individual position values are provided.
| Issuer Name | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|
| Protagonist Therapeutics Inc | 2,449,183 | $300,220,852 | Sole |
| Nanobiotix (Sponsored ADS) | 5,623,816 | $212,017,863 | Sole |
| Contineum Therapeutics Inc | 1,979,173 | $32,438,645 | Sole |
| MeiraGTx Holdings PLC | 6,641,064 | $89,720,775 | Sole |
| Rapport Therapeutics Inc | 1,784,517 | $74,360,823 | Sole |
| CVRX Inc | 4,024,861 | $20,687,786 | Sole |
| Fate Therapeutics Inc | 3,379,064 | $9,123,473 | Sole |
| Cerebras Systems Inc | 53,586 | $11,842,506 | Sole |
| Legend Biotech Corp | 814,586 | $23,525,244 | Sole |
| Neumora Therapeutics Inc | 1,849,445 | $3,144,057 | Sole |
| Xencor Inc | 748,062 | $12,043,798 | Sole |
| Procept Biorobotics Corp | 357,939 | $8,082,263 | Sole |
| Adicet Bio Inc | 22,779 | $196,811 | Sole |
| Vor Biopharma Inc | 53,732 | $989,206 | Sole |
| Standard BioTools Inc | 311,967 | $256,655 | Shared |
Note: The filing does not provide data on Johnson & Johnson's revenue, profit, cash flow, debt, or liquidity. It only reports investment holdings.
Material Changes and Outlook
The filing text does not provide comparative data against prior periods, nor does it include management commentary, guidance, or risk factors regarding Johnson & Johnson's operations. The document strictly lists current holdings and voting authority.
Key Facts for Investor Verification
- Portfolio Concentration: The largest single holding by value is Protagonist Therapeutics Inc ($300.2M), followed by Nanobiotix ($212.0M).
- Sector Focus: The disclosed portfolio is heavily weighted toward biotechnology and life sciences companies.
- Voting Control: Johnson & Johnson reports "Sole" voting authority for 14 of the 15 positions, with "Shared" authority only for Standard BioTools Inc.
- Limitation of Scope: This document does not reflect Johnson & Johnson's own financial health or operational performance.